Cell culture processes for monoclonal antibody production

mAbs

Volumn 2, Issue 5, 2010, Pages 466-479

  Li, Feng ^a   Vijayasankaran, Natarajan ^a   Shen, Amy ^a   Kiss, Robert ^a   Amanullah, Ashraf ^a  

^a GENENTECH INC   (United States)

Author keywords

Cell culture process development; Cell line engineering; Expression systems; Monoclonal antibody; Optimization scale up and technology transfer; Process advances

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; OMALIZUMAB; PANITUMUMAB; RITUXIMAB; TOCILIZUMAB; TRASTUZUMAB;

ALLERGIC ASTHMA; ANIMAL CELL CULTURE; ANTIBODY PRODUCTION; BIOENGINEERING; BIOREACTOR; BIOTECHNOLOGY; BREAST CANCER; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CLONE; COLORECTAL CANCER; DRUG CONTROL; DRUG MANUFACTURE; DRUG QUALITY; HUMAN; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL CULTURE TECHNIQUES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77958518175     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.12720     Document Type: Review

References (100)

1. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22:1393-8.
2. Li F, Hashimura Y, Pendleton R, Harms J, Collins E, Lee B. A systematic approach for scale-down model development and characterization of commercial cell culture processes. Biotechnol Prog 2006; 22:696-703.
3. Kelley B. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. mAbs 2009; 1:443-52.
4. Spens E, Häggström L. Defined protein and animal component-free NS0 fed-batch culture. Biotechnol Bioeng 2007; 98:1183-94.
5. Cruz HJ, Moreira JL, Carrondo MJT. Metabolic shifts by nutrient manipulation in continuous cultures of BHK cells. Biotechnol Bioeng 1999; 66:104-13.
6. Seifert DB, Phillips JA. The production of monoclonal antibody in growth-arrested hybridomas cultivated in suspension and immobilized modes. Biotechnol Prog 1999; 15:655-66.
7. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001; 19:2716-21.
8. Yang J-D, Lu C, Stasny B, Henley J, Guinto W, Gonzalez C, et al. Fed-batch bioreactor process scale-up from 3 L to 2,500 L scale for monoclonal antibody production from cell culture. Biotechnol Bioeng 2007; 98:141-54.
9. Keen MJ, Steward TW. Adaptation of cholesterol-requiring NS0 mouse myeloma cells to high density growth in a fully defined protein-free and cholesterol-free culture medium. Cytotechnology 1995; 17:203-11.
10. Gorfien S, Paul B, Walowitz J, Keem R, Biddle W, Jayme D. Growth of NS0 cells in protein-free, chemically defined medium. Biotechnol Prog 2000; 16:682-7.
11. Seth G, Ozturk M, Hu WS. Reverting cholesterol auxotroph of NS0 cells by altering epigenetic gene silencing. Biotechnol Bioeng 2006; 93:820-7.
12. Hartman TE, Sar N, Genereux K, Barritt DS, He YM, Burky JE, et al. Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol Bioeng 2007; 96:294-306.
13. Birch JR, Racher JR. Antibody production. Adv Drug Delivery Rev 2006; 58:671-85.
14. Li F, Kao E, Ryll TA. Generic High Cell Mass Fed-batch Process for NS0 Cells. Poster Presentation, Cell Culture Engineering IX, March 7-12, 2004; Cancun, Mexico.
15. Burky JE, Wesson MC, Young A, Farnsworth S, Dionne B, Zhu Y, et al. Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol Bioeng 2006; 96:281-93.
16. Alex Z, Rosa H. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 2002; 9:376-81.
17. Byres E, Paton AW, Paton JC, Lofling JC, Smith DF, Wilce MCJ, et al. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 2008; 456:648-52.
18. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003; 100:12045-50.
19. Jones DH, Kroos N, Anema R, Van Montfort B, Vooys A, Van der Kraats S, et al. High-level expression of recombinant IgG in the human cell line PER.C6. Biotechnol Prog 2003; 19:163-8.
20. Jayapal KP, Wlaschin KF, Hu W-S, Yap MGS. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog 2007; 103:40-7.
21. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffher W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 1985; 41:521.
22. Deer JR, Allison DS. High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1 alpha gene. Biotechnol Prog 2004; 20:880-9.
23. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modules translation by eukaryotic ribosomes. Cell 1986; 44:283-92.
24. Shen AY, Van de Goor J, Zheng L, Reyes AE, Krummen LA. Recombinant DNA technology and cell line development. In: Ozturk SS, Hu W-S, eds. Cell culture technology for pharmaceutical and cell-based therapies. Boca Raton, FL: CRC Press, Taylor & Francis Group 2006; 15-40.
25. Davis J, Jiang LY, Pan L-Z, LaBarre MU, Andersen D, Reff M. Expression of GnTIII in recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcyRIII. Biotechnol Bioeng 2001; 74:288-94.
26. Saba JA, Kunkel JP, Jan DCH, Ens WE, Standing KG, Butler M, et al. A study of immunoglobulin G glycosylation in monoclonal and polyclonal species by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 2002; 305:16-31.
27. Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Katsuhiro M, Inoue M, Kitajima-Miyama K, et al. Establishment of a GDP-mannose 4,6-dehydrase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol 2007; 130:300-10.
28. Mori K, Kamochi RK, Ohnuki NY. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 2004; 88:901-8.
29. Sauerwald TM, Figueroa BJ, Hardwick JM, Oyler GA, Betenbaugh MJ. Combining caspase and mitochondrial dysfunction inhibitors of apoptosis to limit cell death in mammalian cell cultures. Biotechnol Bioeng 2006; 94:362-72.
30. Chen K, Liu Q, Xie L-Z, Sharp PA, Wang DI. Engineering of a mammalian cell line for reduction of lactate formation and high monoclonal antibody production. Biotechnol Bioeng 2001; 72:55-61.
31. Kim SH, Lee GM. Downregulation of lactate dehydrogenase-A by siRNAs for reduced lactic acid formation of Chinese hamster ovary cells producing thrombopoietin. Appl Microbiol Biotechnol 2007; 74:152-9.
32. Jeong D-W, Cho IT, Kim TS, Bae GW, Kim I-H, Kim IY. Effects of lactate dehydrogenase suppression and glycerol-3-phosphate dehydrogenase overexpression on cellular metabolism. Mol Cell Biochem 2006; 284:1-8.
33. cip1- arrested CHO cells. Biotechnol Bioeng 2004; 85:741-9.
34. Wolf AP. When more is less. Nat Genet 1998; 18:5-6.
35. Coroadinho AS, Schucht R, Gama-Norton L, Wirth D, Hauser H, Carrondo MJ. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. J Biotechnol 2006; 124:457-68.
36. Fukushige S, Sauer B. Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells. Proc Natl Acad Sci 1992; 89:7905-9.
37. Kito M, Itami S, Fukano Y, Yamana K, Shibui T. Construction of engineered CHO strains for high-level production of recombinant proteins. Appl Microbiol Biotechnol 2002; 60:442-8.
38. Andersen DC, Reilly DE. Production technologies for monoclonal antibodies and their fragments. Curr Opinion Biotechnol 2004; 15:456-62.
39. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotech 2006; 24:210-5.
40. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263:133-47.
41. Mazor Y, Van Blarcom V, Mabry R, Iverson BL, Georgiou G. Isolation of engineered, full length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007; 25:563-5.
42. Ward M, Lin C, Victoria DC, Fox BP, Fox JA, Wong DL, et al. Characterization of Humanized Antibodies Secreted by Aspergillus niger. Appl Environ Microbiol 2004; 70:2567-76.
43. Goerke AR, Swartz JR. Development of cell-free protein synthesis platforms for disulfide bonded proteins. Biotechnol Bioeng 2008; 99:351-67.
44. Butler M. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 2005; 68:283-91.
45. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotech 2006; 24:1241-52.
46. Gawlitzek M, Estacio M, Furch T, Kiss R. Identification of cell culture conditions to control N-glycosylation site-cccupancy of recombinant glycoproteins expressed in CHO cells. Biotechnol Bioeng 2009; 103:1164-75.
47. Fletcher T. Designing culture media for recombinant protein production: A rational approach. BioProcess International 2005; 3:30-6.
48. Vijayasankaran N, Li J, Shawley R, Chen A, Shiratori M, Gawlitzek M, et al. Animal Cell Culture Media. In: Flickinger MC, ed. Encyclopedia of Industrial Biotechnology, Bioprocess, Bioseparation, and Cell Technology: John Wiley & Sons, Inc., 2010.
49. Heidemann R, Zhang C, Qi H, Larrick Rule J, Rozales C, Park S, et al. The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells. Cytotechnology 2000; 32:157-67.
50. Franek F, Hohenwarter O, Katinger H. Plant protein hydrolysates: Preparation of defined peptide fractions promoting growth and production in animal cells cultures. Biotechnol Prog 2000; 16:688-92.
51. Zhou W, Rehm J, Europa A, Hu W-S. Alteration of mammalian cell metabolism by dynamic nutrient feeding. Cytotechnology 1997; 24:99-108.
52. Zhou W, Rehm J, Hu WS. High viable cell concentration fed-batch cultures of hybridoma cells through on-line nutrient feeding. Biotechnol Bioeng 1995; 46:579-87.
53. Xie LZ, Wang DIC. High cell density and high monoclonal antibody production through medium design and rational control in a bioreactor. Biotechnol Bioeng 1996; 51:725-9.
54. Castro PML, Hayter PM, Ison AP, Bull AT. Application of a statistical design to the optimization of culture medium for recombinant interferon-gamma production by Chinese hamster ovary cells. Appl Microbiol Biotechnol 1992; 38:84-90.
55. Hammett K, Kuchibhatla J, Hunt C, Holdread S, Brooks J. Developing chemically defined media through DOE: Complete optimization with increased protein production in less than 8 Months. In: Smith R, ed. Cell Technology for Cell Products. Dordrecht, Netherlands: Springer Netherlands 2007;683-91.
56. Harcum S. Protein glycosylation. In: Ozturk SS, Hu WS, eds. Cell culture technology for pharmaceutical and cell-based therapies. Boca Raton, FL: CRC Press 2006:113-53.
57. Guidance for Industry PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Food and Drug Administration (FDA) 2004.
58. Gnoth S, Jenzsch M, Simutis R, Lübbert A. Process Analytical Technology (PAT): Batch-to-batch reproducibility of fermentation processes by robust process operational design and control. J Biotechnol 2007; 132:180-6.
59. Furukawa K, Ohsuye K. Enhancement of productivity of recombinant α-amidating enzyme by low temperature culture. Cytotechnology 1999; 31:85-94.
60. Moore A, Mercer J, Dutina G, Donahue CJ, Bauer KD, Mather JP, et al. Effects of temperature shift on cell cycle, apoptosis and nucleotide pools in CHO cell batch culture. Cytotechnology 1997; 23:47-54.
61. Fox SR, Tan HK, Tan MC, Wong SC, Yap MG, Wang DI, et al. A detailed understanding of the enhanced hypothermic productivity of interferon-gamma by Chinese-hamster ovary cells. Biotechnol Appl Biochem 2005; 41:255-64.
62. Fleischaker RJ, Sinskey AJ. Oxygen demand and supply in cell culture. Appl Microbiol Biotechnol 1981; 12:193-7.
63. Miller WM, Wilke CR, Blanch HW. Effect of dissolved oxygen on hybridoma growth and metabolism in continuous culture. J Cell Physiol 1987; 132:524-30.
64. Ozturk SS, Palsson BO. Effects of dissolved oxygen on hybridoma cell growth, metabolism and antibody production kinetics in continuous cultures. Biotechnol Prog 1990; 6:437-46.
65. Kunkel JP, Jan DCH, Jamieson JC, Bulter M. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J Biotechnol 1998; 62:55-71.
66. Garnier A, Voyer R, Tom R, Perret S, Jardin B, Kamen A. Dissolved carbon dioxide accumulation in a large scale high cell density production of TGFβ receptor with baculovirus infected Sf-9 cells. Cytotechnology 1996; 22:53-63.
67. 2 in large-scale and high density CHO cell perfusion culture. Cytotechnology 1996; 22:65-78.
68. 2. Biotechnol Prog 1997; 73:311-7.
69. Wayte J, Boraston R, Bland H, Varley J, Brown M. pH: effects on growth productivity of cell lines producing monoclonal antibodies: control in large scale fermenters. Cytotechnology 1997; 22:87-94.
70. Schmid G, Blanch HW, Wilke CR. Hybridoma growth, metabolism and product formation in HEPES-buffered media: II: Effect of pH. Biotechnol Lett 1990; 12:633-8.
71. 2 and osmolality: intracellular pH, cell size, apoptosis and metabolism. Biotechnol Bioeng 2002; 77:369-80.
72. 2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: A case study. Biotechnol Prog 2005; 21:70-7.
73. Maiorella B, Inlow D, Howarth W. Method of increasing product expression through solute stress. United States Patent US 6,238,891 B1.
74. Chen M, Forman LW. Polypeptide production in animal cell culture. United States Patent US 6,180,401 B1.
75. Seewöster T, Lehmann J. Cell size distribution as a parameter for the predetermination of exponential growth during repeated batch cultivation of CHO cells. Biotechnol Bioeng 1997; 55:793-7.
76. Xing Z, Kenty BM, Li ZJ, Lee SS. Scale-up analysis for a CHO cell culture process in large-scale bioreactors. Biotechnol Bioeng 2009; 103:733-46.
77. Rathore AS, Noferi JF, Arling ER, Sofer G, Watler P, O'Leary R. Process validation how much to do and when to do it. BioPharm International 2002; 15:18-28.
78. FDA Guidance for Industry: Q5E Comparability of Biotechnological/ Biological Products Subject to Changes in Their Manufacturing Process. June 2005, http://wwwfdagov/cder/guidance/indexhtm.
79. Rathore AS, Wang A, Menon M, Riske F, Campbell J, Goodrich E, et al. Optimization, scale-up and validation issues in filtration of biopharmaceuticals- Part I. BioPharm International 2004; 17:50-8.
80. Seely JE, Seely R. A rational, step-wise approach to process characterization. BioPharm Int 2003; 16:24-34.
81. Goochee CF. The roles of a process development group in biopharmaceutical process startup. Cytotechnology 2002; 38:63-76.
82. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22:1383-91.
83. Kensy F JG, Hofmann B, Büchs J. Characterization of operation conditions and online monitoring of physiological culture parameters in shaken 24-well microtiter plates. Bioprocess Biosyst Eng 2005; 75:75-81.
84. Micheletti M, Barrett T, Doig SD, Baganz F, Levy MS, Woodley JM, et al. Fluid mixing in shaken bioreactors: implications for scale-up predictions from microliter-scale microbial and mammalian cell cultures. Chemical Engineering Science 2006; 61:2939-49.
85. De Jesus MJ, Girard P, Bourgeois M, Baumgartner G, Jacko B, Amstutz H, et al. TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology. Biochem Eng J 2004; 17:217-23.
86. Legmann R, Schreyer HB, Combs RG, McCormick EL, Russo AP, Rodgers ST. A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells. Biotechnol Bioeng 2009; 104: 1107-20.
87. Chen A, Chitta R, Chang D, Amanullah A. Twenty-four well plate miniature bioreactor system as a scale-down model for cell culture process development. Biotechnol Bioeng 2009; 102:148-60.
88. Amanullah A, Otero JM, Mikola MR, Hsu A, Zhang J, Aunins J, et al. Evaluation of Simcell technology for cell culture process development. Biochemical Engineering XV, Quebec City, Canada 2007; July 15-19 2007.
89. Derfus GE, Abramzon D, Tung M, Chang D, Kiss R, Amanullah A. Cell culture monitoring via an auto-sampler and an integrated multi-functional off-line analyzer. Biotechnol Prog 26:284-92.
90. Konstantinov KB, Pambuyan R, Matanguihan R, Yoshida T, Purusich CM, Hu WS. On-line monitoring of hybridoma cell growth using a laser turbidity sensor. Biotechnol Bioeng 1992; 40:1337-42.
91. Zeiser A, Bedard C, Voyer R, Jardin B, Tom R, Kamen A. On-line monitoring of the progress of infection in Sf-9 insect cell cultures using relative permittivity measurements. Biotechnol Bioeng 1999; 63:122-6.
92. Chung H, Arnold M, Rhiel M, Murhammer D. Simultaneous measurement of glucose and glutamine in aqueous solutions by near infrared spectroscopy. Appl Biochem Biotechnol 1995; 50:109-25.
93. Riley MR, Okeson CD, Frazier BL. Rapid calibration development for near-infrared spectroscopic monitoring of mammalian cell cultivations. Biotechnol Prog 1999; 15:1133-41.
94. Riley MR, Crider HM, Nite ME, Garcia RA, Woo J, Wegge RM. Simultaneous measurements of 19 components in animal cell culture media by near infrared spectroscopy. Biotechnol Prog 2001; 17:376-8.
95. Yano T, Harata M. Prediction of the concentration of several constituents in a mouse-mouse hybridoma culture by near infrared spectroscopy. J Ferment Bioeng 1994; 77:659-62.
96. Harms PKY, French JA, Soliman M, Anjanappa M, Ram A, Rao G. Design and performance of a 24-station high throughput microbioreactor. Biotechnol Bioeng 2006; 93:6-13.
97. Eibl D, Eibl R. Bioreactors for Mammalian Cells: General Overview. Cell and Tissue Reaction Engineering: Springer Berlin Heidelberg 2008; 55-82.
98. Eibl R, Eibl D. Disposable bioreactors for cell culture based-bioprocessing. Achema Worldwide News 2007; 8-10.
99. Seth G, Philp RJ, Lau A, Jiun KY, Yap M, Hu WS. Molecular portrait of high productivity in recombinant NS0 cells. Biotechnol Bioeng 2006; 97:933-51.
100. Wlaschin KF, Seth G, Hu WS. Toward genomic cell culture engineering. Cytotechnology 2006; 50:121-40.